KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
The team also elucidated well-established and controversial non-BRCA predisposition genes associated with breast or ovarian cancer.
The effort will provide individuals with genetic testing to determine if they have the disorder, and when necessary, with genetic testing counselling.
Ambry will offer ArcherDX's immune repertoire sequencing assays to biopharmaceutical customers.
Researchers from Ambry Genetics analyzed a set of DTC results sent to them for confirmation testing and found that 40 percent were false positives.
The partnership will integrate Ambry Genetics' and Invicro's technologies to expedite new drug discovery and development.
Konica Minolta paid $800 million up front for Ambry, with Ambry shareholders eligible to receive up to $200 million in future payments.
The deal will join the AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.
Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.
The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.